Innovative Therapy Revolutionizes Treatment for Leukemia Patients, Demonstrating Exceptional Results in Clinical Trials
Topics covered
In a significant advancement for cancer treatment, researchers have developed a new therapy that manipulates immune cells to combat a rare and aggressive type of leukemia. This groundbreaking therapy, known as BE-CAR7, has yielded positive results in clinical trials, offering renewed hope for both adults and children diagnosed with T-cell acute lymphoblastic leukemia (T-ALL), a condition previously considered difficult to treat.
Conducted by experts at Great Ormond Street Hospital and University College London, BE-CAR7 has demonstrated remarkable efficacy. Nearly two-thirds of participants in the trial have remained free of the disease, marking a significant milestone in the ongoing battle against blood cancers.
Understanding BE-CAR7 and its development
The innovative approach behind BE-CAR7 is an evolution of the existing CAR T-cell therapy. Traditional CAR T-cell treatments involve extracting T cells from a patient, modifying them in a laboratory by attaching chimeric antigen receptors (CARs) to their surfaces, and then reintroducing them into the patient’s bloodstream.
This process allows the immune cells to target and eliminate cancerous cells.
However, the challenge has been to adapt this technology for T-ALL, which originates from abnormal T cells. BE-CAR7 circumvents this issue by utilizing healthy T cells from donors, creating a readily available, or off-the-shelf, treatment option. This method employs a sophisticated technique known as base editing, enabling the modified T cells to remain effective even after chemotherapy and preventing them from attacking normal cells.
The technology behind base editing
Base editing represents a significant leap forward in gene editing methodology, building on the groundwork laid by the CRISPR technology, which garnered the Nobel Prize in Chemistry. This technique allows scientists to make precise alterations to single DNA letters within living cells, offering a powerful tool for therapeutic applications.
In a clinical trial, the efficacy of BE-CAR7 was evaluated in preparation for bone marrow transplants, aiming to eliminate leukemia and reduce the risk of recurrence. Eleven patients, including nine children and two adults, participated in the study at both Great Ormond Street Hospital and King’s College Hospital.
Positive outcomes and patient experiences
The results have been encouraging, with approximately 64% of the trial participants remaining cancer-free, some of whom have been off treatment for three years. Furthermore, over 82% achieved substantial remission, enabling them to undergo stem cell transplants without the presence of the disease.
While some side effects were reported, including low blood counts and skin rashes, the overall tolerance levels were deemed manageable by the research team. Professor Waseem Qasim, a key figure in the study, noted that these results highlight the potential of universal, base-edited CAR T-cells in addressing resistant cases of CD7+ leukemia.
Alyssa’s journey with BE-CAR7
Among the participants was Alyssa Tapley, a 16-year-old from Leicester, who volunteered for the trial after her diagnosis of T-cell leukemia. Alyssa had not responded to conventional treatments and decided to participate in the research, motivated by the possibility of benefiting others. Reflecting on her experience, she expressed her gratitude and optimism for the future, stating, “I’m doing really well and hope to contribute to research that can help others in similar situations.”
Dr. Deborah Yallop, a consultant hematologist involved in the study, praised the impressive outcomes of the therapy, emphasizing its potential to clear previously incurable leukemia. The trial results were published in the esteemed New England Journal of Medicine and presented at the 67th Annual Meeting of the American Society of Hematology, further solidifying the therapy’s significance in the field.
Future implications and ongoing research
Conducted by experts at Great Ormond Street Hospital and University College London, BE-CAR7 has demonstrated remarkable efficacy. Nearly two-thirds of participants in the trial have remained free of the disease, marking a significant milestone in the ongoing battle against blood cancers.0
Conducted by experts at Great Ormond Street Hospital and University College London, BE-CAR7 has demonstrated remarkable efficacy. Nearly two-thirds of participants in the trial have remained free of the disease, marking a significant milestone in the ongoing battle against blood cancers.1
